ES2614355T3 - Derivados de glicina N-sustituida con piridazin-diona como inhibidores de HIF hidoxilasas - Google Patents

Derivados de glicina N-sustituida con piridazin-diona como inhibidores de HIF hidoxilasas Download PDF

Info

Publication number
ES2614355T3
ES2614355T3 ES14196983.2T ES14196983T ES2614355T3 ES 2614355 T3 ES2614355 T3 ES 2614355T3 ES 14196983 T ES14196983 T ES 14196983T ES 2614355 T3 ES2614355 T3 ES 2614355T3
Authority
ES
Spain
Prior art keywords
formula
compound
pharmaceutically acceptable
oxo
methylethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14196983.2T
Other languages
English (en)
Spanish (es)
Inventor
Kevin J. Duffy
Antony N. Shaw
William Henry Miller
Andrea K. Myers
Michael N. Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39636631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2614355(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Application granted granted Critical
Publication of ES2614355T3 publication Critical patent/ES2614355T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
ES14196983.2T 2007-01-12 2008-01-11 Derivados de glicina N-sustituida con piridazin-diona como inhibidores de HIF hidoxilasas Active ES2614355T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88471007P 2007-01-12 2007-01-12
US884710P 2007-01-12

Publications (1)

Publication Number Publication Date
ES2614355T3 true ES2614355T3 (es) 2017-05-30

Family

ID=39636631

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14196983.2T Active ES2614355T3 (es) 2007-01-12 2008-01-11 Derivados de glicina N-sustituida con piridazin-diona como inhibidores de HIF hidoxilasas
ES08727581.4T Active ES2528745T3 (es) 2007-01-12 2008-01-11 Derivados de glicina N-sustituida: inhibidores de hidoxilasas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES08727581.4T Active ES2528745T3 (es) 2007-01-12 2008-01-11 Derivados de glicina N-sustituida: inhibidores de hidoxilasas

Country Status (20)

Country Link
US (2) US7608621B2 (enExample)
EP (2) EP2889289B1 (enExample)
JP (1) JP5313925B2 (enExample)
KR (1) KR101458655B1 (enExample)
CN (1) CN101626685B (enExample)
AR (1) AR064878A1 (enExample)
AU (1) AU2008206441B2 (enExample)
BR (1) BRPI0806566A2 (enExample)
CA (1) CA2675252C (enExample)
CL (1) CL2008000066A1 (enExample)
DK (1) DK2124565T3 (enExample)
EA (1) EA017112B1 (enExample)
ES (2) ES2614355T3 (enExample)
HR (1) HRP20150119T1 (enExample)
MX (1) MX2009007548A (enExample)
PL (1) PL2124565T3 (enExample)
PT (1) PT2124565E (enExample)
SI (1) SI2124565T1 (enExample)
TW (1) TW200845991A (enExample)
WO (1) WO2008089052A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040672A1 (es) * 2002-07-25 2005-04-13 Glaxo Group Ltd Forma de dosificacion farmaceutica multicomponenete, cuerpo apropiado para ser utilizado en la misma y procedimiento para prepararla
CN101212967A (zh) 2005-05-10 2008-07-02 因塞特公司 吲哚胺2,3-双加氧酶调节剂及其用法
ITMI20051085A1 (it) * 2005-06-10 2006-12-11 Acs Dobfar Spa Metodo di purificazione del cefotetan
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
AU2007265460B2 (en) 2006-06-26 2011-03-03 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
CA2663057C (en) * 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
CN104042611B (zh) 2008-07-08 2019-05-14 因塞特控股公司 作为吲哚胺2，3-双加氧酶的抑制剂的1，2，5-噁二唑
EP2334682B1 (en) 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
EP2326179A4 (en) * 2008-08-25 2011-08-17 Smithkline Beecham Corp PROLYLHYDROXYLASEHEMMER
JP5631741B2 (ja) * 2008-11-13 2014-11-26 日本農薬株式会社 ピラジン誘導体類の製造方法及びその中間体類
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
DE102009004061A1 (de) * 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
AR077417A1 (es) * 2009-07-17 2011-08-24 Japan Tobacco Inc Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa o agente inductor de la produccion de eritropoyetina
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
RS54323B1 (sr) * 2009-10-21 2016-02-29 Daiichi Sankyo Company, Limited Derivat 5-hidroksipirimidin-4-karboksamida
PH12012500788A1 (en) 2009-11-06 2016-07-27 Aerpio Therapeutics Inc Compositions and methods for treating colitis
WO2011115687A2 (en) * 2010-03-19 2011-09-22 Northwestern University Alkylated sp-b peptoid compounds and related lung surfactant compositions
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
US8865748B2 (en) 2011-06-06 2014-10-21 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (enExample) 2011-06-06 2018-03-17
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
BR112014009910B1 (pt) 2011-10-25 2020-06-30 Janssen Pharmaceutica N.V. sal di-hidrato de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico, composição farmacêuticae pomada tópica
IN2015DN01035A (enExample) 2012-07-30 2015-06-26 Taisho Pharmaceutical Co Ltd
MY204336A (en) 2013-06-13 2024-08-23 Akebia Therapeutics Inc Compositions and methods for treating anemia
MY174254A (en) 2013-11-08 2020-04-01 Incyte Holdings Corp Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
CN114890943A (zh) 2013-11-15 2022-08-12 阿克比治疗有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途
EP3190104B1 (en) 2014-09-02 2021-10-27 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії
CN105130888A (zh) * 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CA3001065A1 (en) 2015-10-14 2017-04-20 Xiaoxi WEI Compositions and methods for reducing ice crystal formation
MX2020011845A (es) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021127273A1 (en) * 2019-12-20 2021-06-24 Gb004, Inc. 1 -((6-oxo-1,6-dihydropyridazin-4-yl)methyl)piperazine and 1 -((6-oxo-1,6-dihydropyrimidin-4-yl)methyl)piperazine derivatives as prolyl hydroxylase, hif-1 alpha and pgk modulators for use in treating inflammatory diseases, cancer or infections
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
US6972296B2 (en) * 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US20030176317A1 (en) 2001-12-06 2003-09-18 Volkmar Guenzler-Pukall Stabilization of hypoxia inducible factor (HIF) alpha
US6878709B2 (en) * 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
WO2003088917A2 (en) 2002-04-19 2003-10-30 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US7718624B2 (en) 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
JP5390184B2 (ja) * 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
WO2008013838A2 (en) 2006-07-25 2008-01-31 Cephalon, Inc. Pyridizinone derivatives
US20090011051A1 (en) 2006-09-28 2009-01-08 Roth Mark B Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds
WO2008073292A2 (en) 2006-12-08 2008-06-19 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands

Also Published As

Publication number Publication date
EP2124565B1 (en) 2015-01-07
KR20090101376A (ko) 2009-09-25
JP5313925B2 (ja) 2013-10-09
MX2009007548A (es) 2009-07-22
US20080214549A1 (en) 2008-09-04
USRE44613E1 (en) 2013-11-26
KR101458655B1 (ko) 2014-11-05
CN101626685A (zh) 2010-01-13
BRPI0806566A2 (pt) 2014-05-06
CL2008000066A1 (es) 2008-08-01
WO2008089052A3 (en) 2008-09-18
AU2008206441B2 (en) 2014-06-19
EP2124565A2 (en) 2009-12-02
EP2124565A4 (en) 2011-06-29
EA200970680A1 (ru) 2010-02-26
EA017112B1 (ru) 2012-09-28
CA2675252A1 (en) 2008-07-24
EP2889289A1 (en) 2015-07-01
AR064878A1 (es) 2009-04-29
CN101626685B (zh) 2013-03-13
PL2124565T3 (pl) 2015-05-29
JP2010515756A (ja) 2010-05-13
CA2675252C (en) 2015-05-26
EP2889289B1 (en) 2016-12-21
US7608621B2 (en) 2009-10-27
PT2124565E (pt) 2015-03-26
SI2124565T1 (sl) 2015-04-30
DK2124565T3 (en) 2015-02-09
TW200845991A (en) 2008-12-01
WO2008089052A2 (en) 2008-07-24
HRP20150119T1 (hr) 2015-05-08
ES2528745T3 (es) 2015-02-12
AU2008206441A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
ES2614355T3 (es) Derivados de glicina N-sustituida con piridazin-diona como inhibidores de HIF hidoxilasas
US20100305154A1 (en) Prolyl Hydroxylase Inhibitors
WO2010059552A1 (en) Prolyl hydroxylase inhibitors
US20090176825A1 (en) Prolyl hydroxylase inhibitors
WO2009039321A1 (en) Prolyl hydroxylase inhibitors
WO2009039323A1 (en) Prolyl hydroxylase inhibitors
US20110144167A1 (en) Prolyl Hydroxylase Inhibitors
US20110160227A1 (en) Prolyl Hydroxylase Inhibitors
ES2316546T3 (es) 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
US7897612B2 (en) Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors
US20110039895A1 (en) Prolyl hydroxylase inhibitors
WO2009049112A1 (en) Prolyl hydroxylase inhibitors
JPWO2008120725A1 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2009039322A1 (en) Prolyl hydroxylase inhibitors
EP2306828A1 (en) Prolyl hydroxylase inhibitors
WO2023224998A1 (en) Inhibitors of parg
US8697697B2 (en) Pyrazole derivatives as ERK inhibitors
AU2023271807A1 (en) Inhibitors of parg
CN114524810B (zh) 一类嘧啶并杂环类化合物、制备方法和用途
WO2010059549A1 (en) Prolyl hydroxylase inhibitors
WO2010022308A1 (en) Prolyl hydroxylase inhibitors
WO2009134847A1 (en) Prolyl hydroxylase inhibitors
WO2010059555A1 (en) Prolyl hydroxylase inhibitors
CN118852164A (zh) Parp选择性抑制剂